Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.
Year: 2021
Type: article
Abstract: designed the first OV-BiTE in 2014, which remarkably eradicated tumors in mice. Here we review the latest development of the structure, function, preclinical studies and/or clinical trials of BiTE and OV-BiTE and provide perspective views for optimizing the design of OV-BiTE. There is no doubt that OV-BiTE is becoming an exciting new platform for tumor immunotherapy and will enter clinical trial soon. Exploring the therapeutic effects and safety of OV-BiTE for synergistic tumor immunotherapy will bring new hope to tumor patients.
Source: PubMed Central
Authors: Qi Huang, Wen-Qi Cai, Zi-Wen Han, Mo-Yu Wang, Yang Zhou, Jun-Ting Cheng, Ying Zhang, Ying-Ying Wang, Qiang Xin, Xian-Wang Wang, Xiao-Chun Peng, Ying Xiang, Shu-Xian Fang, Zhao-Wu Ma, Hong-Yi Xin, Shu-Zhong Cui, Hong-Wu Xin
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3181883167
